Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOR/ISL switch in virologically suppressed HIV-1
NCT04223778Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 3 trial of doravirine, islatravir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Merck & Co.. Started Feb 2020; status: completed.
02
Drugs
doravirineislatravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04223778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04223778.